Table 3.

Metastatis sites and metachronous contralateral breast carcinoma in patient groups according to histological types

	ILC		IDC		IDLC		p
Metastasis sites	n	%	n	%	n	%	ILC vs IDC	ILC vs IDLC	IDC vs IDLC
Axillary lymph nodes							0.929	0.410	0.325
Yes	4	1.5	52	1.7	5	3.1
No	268	98.5	2929	98.3	154	96.9
Bone							0.162	0.085	0.001
Yes	54	19.9	493	16.5	43	27.0
No	218	80.1	2488	83.5	116	73.0
Lung							0.429	1.000	0.700
Yes	25	9.2	320	10.7	15	9.4
No	247	90.8	2661	89.3	144	90.6
Pleura							0.961	0.591	0.306
Yes	4	1.5	51	1.7	5	3.1
No	268	98.5	2930	98.3	154	96.9
Liver							0.779	0.519	0.574
Yes	18	6.6	217	7.3	14	8.8
No	254	93.4	2764	92.7	145	91.2
Central nervous system							0.071	1.000	0.235
Yes	3	1.1	98	3.3	2	1.3
No	269	98.9	2883	96.7	157	98.7
Gynecologic							1.000	1.000	1.000
Yes	1	0.4	6	0.2	0	0.0
No	271	99.6	2975	99.8	159	100.0
Distant lymph nodes							0.146	1.000	0.265
Yes	10	3.7	63	2.1	6	3.8
No	262	96.3	2918	97.9	153	96.2
Skin-subcutaneous							0.545	1.000	1.000
Yes	1	0.4	8	0.3	0	0.0
No	271	99.6	2973	99.7	159	100.0
Adrenal							1.000	-	1.000
Yes	0	0.0	5	0.2	0	0.0
No	272	100.0	2976	99.8	159	100.0
Peritoneum							0.354	1.000	0.229
Yes	1	0.4	4	0.1	1	0.6
No	271	99.6	2977	99.9	158	99.4
Contralateral breast carcinoma							0.496	0.252	0.405
Yes	3	1.1	56	1.9	5	3.1
No	269	98.9	2925	98.1	154	96.9

ILC: invasive lobular carcinoma; IDC: invasive ductal carcinoma; IDLC: mixed invasive ductal and lobular carcinoma